HBK Investments’s Kite Pharma, Inc. KITE Stock Holding History

HBK Investments’s Portfolio KITE Stock Details KITE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-11,501	Closed	-$528K	–	1171
2016 Q1	$528K	Buy	11,501 +4,871	+73%	+$236K	0.01%	722
2015 Q4	$409K	Buy	+6,630	New	+$467K	﹤0.01%	796
2015 Q2	–	Sell	-4,797	Closed	-$277K	–	1189
2015 Q1	$277K	Buy	+4,797	New	+$321K	﹤0.01%	873

Other funds holding KITE

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

WCM

Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

HBK Investments's KITE Position: Q2 2016 in Review

HBK Investments sold out of Kite Pharma, Inc. (KITE) in Q2 2016, closing a stake of 11,501 shares — an estimated $528K sold.

HBK Investments first reported a position in KITE in Q1 2015 and held it in 3 quarters. The position peaked at $528K in Q1 2016. 173 funds tracked by Wall St. Rank hold KITE as of Q2 2016.

HBK Investments reported no remaining Kite Pharma, Inc. position as of Q2 2016 after selling out during the quarter.
HBK Investments sold 11,501 Kite Pharma, Inc. shares in Q2 2016, an estimated $528K.
HBK Investments first reported a position in Kite Pharma, Inc. in Q1 2015 and held it in 3 quarters.
HBK Investments's Kite Pharma, Inc. position peaked at $528K in Q1 2016.
173 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q2 2016.

Based on HBK Investments's 13F filing for Q2 2016, filed 15 Aug 2016.